Ascletis initiates dosing in a global Phase III trial of its oral GLP-1 agonist ASC30 for chronic weight management, aiming to challenge injectable obesity therapies
Executive summary: Ascletis dosed the first participant in its global Phase III program for oral GLP‑1 receptor agonist ASC30, targeting chronic weight management, with plans to enroll about 4,600 participants in the AURORA‑1 and AURORA‑2 trials in the US, Europe and Canada. The study will test three dose levels to determine whether ASC30 can deliver comparable weight‑loss efficacy to injectable GLP‑1 therapies while offering the convenience of an oral pill, which could capture a share of the fast‑growing obesity treatment market.
Who is involved: Ascletis (sponsor), clinical investigators in the United States, Europe and Canada, eligible participants with obesity or overweight, and regulatory bodies including the FDA and EMA overseeing the Phase III process.
Likely next: Continued enrollment toward the 4,600‑patient target, interim safety and efficacy readouts expected in 2027, and, if results are positive, preparation of new drug applications for regulatory submission in the late 2020s.
Ascletis announced that the first participant has been dosed in its AURORA-1 and AURORA-2 studies, which together plan to enroll roughly 4,600 obese or overweight adults across the United States, Europe and Canada. The trial will evaluate three maintenance doses (20 mg, 40 mg and a higher dose) of the once‑daily oral small‑molecule GLP-1 receptor agonist ASC30 for efficacy and safety. Positive outcomes could provide an oral alternative to current injectable GLP-1 drugs such as semaglutide and tirzepatide, potentially shifting prescribing patterns and expanding the company’s addressable market.
Timeline
- — Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management (PR Newswire)
- — Ascletis Announces Initiation of Global Phase III for Oral Small Molecule GLP-1, ASC30 and Positive Preclinical Data for Its First-in-Class Oral Small Molecule GLP-1/GIP/Amylin Fixed-Dose Combination (PR Newswire)
Analysis — what this means
Likely next events
- Enrollment completion projected for Q2 2027
- First efficacy readout anticipated in H2 2027
- Potential NDA submission targeted for late 2028
Sectors affected
- Obesity therapeutics
- GLP-1 receptor agonist market
- Oral diabetes/weight management drugs
Regulatory implications
- FDA will require comprehensive safety data for the oral GLP-1 class before approval
- EMA will assess ASC30 under the centralized procedure, focusing on cardiovascular safety
Historical parallels
- Lilly’s oral GLP‑1 candidate (orforglipron) entered Phase III testing in 2023
- Pfizer halted its oral GLP‑1 program in 2022 after safety concerns emerged in early trials
Key entities
Sources
Open the full interactive case file on Beyond →